Review: Metformin does not increase risk for lactic acidosis or increase lactate levels in type 2 diabetes

Kruse, James A.
July 2004
ACP Journal Club;Jul/Aug2004, Vol. 141 Issue 1, p7
Academic Journal
The article focuses on the fact that metformin does not increase risk for lactic acidosis or increase lactate levels in type 2 diabetes. Studies were selected if they were randomized controlled trials (RCTs) or cohort studies 1 month in duration that compared metformin, alone or in combination with other treatments, with placebo or another glycemic-lowering intervention for type 2 diabetes. Since its introduction in the United States in 1995, the biguanide drug metformin has been widely prescribed as an effective oral antihyperglycemic drug for the treatment of diabetes mellitus.


Related Articles

  • Tailored support for type 2 diabetes patients with an acute coronary event after discharge from hospital - design and development of a randomised controlled trial. Kasteleyn, Marise J.; Gorter, Kees J.; Stellato, Rebecca K.; Rijken, Mieke; Nijpels, Giel; Rutten, Guy E. H. M. // Diabetology & Metabolic Syndrome;2014, Vol. 6 Issue 1, p2 

    Background Type 2 diabetes mellitus patients with an acute coronary event (ACE) experience decreased quality of life and increased distress. According to the American Diabetes Association, discharge from the hospital is a time of increased distress for all patients. Tailored support specific to...

  • Cinnamon May Help to Alleviate Diabetes Says UC Santa Barbara Researcher.  // Ascribe Newswire: Medicine;4/12/2004, p69 

    Cinnamon may help by playing the role of an insulin substitute in type II diabetes, according to cellular and molecular studies at the University of California, Santa Barbara (UCSB), Iowa State University and the U.S. Department of Agriculture. The healthful effects of cinnamon on mice with...

  • Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus. Kaushal, Shaveta; Singh, Harmanjit; Thangaraju, Pugazhenthan; Singh, Jasbir // North American Journal of Medical Sciences;Mar2014, Vol. 6 Issue 3, p107 

    Diabetes Mellitus continues to be a major non- communicable disease with global burden of 366 million at present and projected to increase to 439 to 552 million by 2030, India being the hub of diabetes. Sodium glucose transporter 2 (SGLT2) inhibitors presents a new class of anti-diabetic drugs...

  • Strategies to Identify Adults at High Risk for Type 2 Diabetes.  // Diabetes Care;Jan2005, Vol. 28 Issue 1, p138 

    OBJECTIVE -- The Diabetes Prevention Program (DPP) was a large, multicenter, randomized clinical trial testing interventions to prevent or delay type 2 diabetes. A major challenge was to identify eligible high-risk adults, defined by DPP as having both impaired glucose tolerance (IGT) (2-h...

  • Primary Prevention of Type 2 Diabetes: Lifestyle Intervention Works and Saves Money, but What Should Be Done with Smokers? Tuomilehto, Jaakko // Annals of Internal Medicine;3/1/2005, Vol. 142 Issue 5, p381 

    This article focuses on the primary prevention of type 2 diabetes. A successful preventive intervention must, therefore, target several risk factors simultaneously. This characteristic of preventive interventions means that they are necessarily complex and require considerable resources....

  • The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Charbonnel, Bernard; Dormandy, John; Erdmann, Erland; Masssi-Benedetti, Massimo; Skene, Allan; Massi-Benedetti, Massimo; PROactive Study Group // Diabetes Care;Jul2004, Vol. 27 Issue 7, p1647 

    Objective: The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) assesses the effect of pioglitazone, a peroxisome proliferator-activated receptor agonist, with anti-inflammatory and vascular properties, on the secondary prevention of macrovascular events...

  • CITATIONS AND CLINICIANS' NOTES: HYPERTENSION -- TREATMENT.  // Current Medical Literature: Nephrology & Hypertension;2005, Vol. 11 Issue 1, p21 

    The article presents information on several studies related to the treatment of hypertension. The study "Systolic hypertension in Older Persons," by S.I. Chaudhry, H.M. Krumholz, and J.M. Foody, reviewed the available literature on the clinical management of systolic hypertension in elderly...

  • LINAGLIPTIN- A NOVEL DPP-IV INHIBITOR. Prabavathy, N.; Vijayakumari, M.; Minil, M.; Sathiyaraj, U.; Kavimani, S. // International Journal of Pharma & Bio Sciences;Jan-Mar2011, Vol. 2 Issue 1, pP438 

    Although glycemic control is an important and effective way to prevent and minimize the worsening of diabetes-related complications, type 2 diabetes is a progressive disease which often proves difficult to manage. Most affected patients will eventually require therapy with multiple medications...

  • The Effects of a Computer-Tailored Message on Secondary Prevention in Type 2 Diabetes: A Randomized Trial. Adams, Sandra Y.; Crawford, Albert G.; Rimal, Rajiv N.; Lee, Joyce S.; Janneck, Laura M.; Sciamanna, Christopher N. // Population Health Management;Aug2009, Vol. 12 Issue 4, p197 

    The purpose of this study was to test the effect of computer-generated, tailored feedback on the quality of chronic disease management for type 2 diabetes when provided to a patient prior to a scheduled physician visit. A stand-alone computer application was developed to provide tailored...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics